For decades, multiple myeloma (MM) has been considered a disease of the elderly, with few therapeutic options apart from alkylators and corticosteroids. The treatment goal was disease control, with response rates of 50%, with occasional complete responses (CRs) and median survival of 2–3 years.[1
No takes yet. Share an insight, caveat, or question.
Miguel et al. (2011) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: